Table II:
Current registered and ongoing trials for AH
| AH targets | Drug types | Trial design | Title/trial number |
|---|---|---|---|
| Lipid metabolism, inflammation | DUR-928 (sulfated oxysterol) | DUR-928 dose-escalation | DUR-928 in patients with AH/ NCT03917407 |
| Lipid metabolism, inflammation | 5-lipoxygenase inhibitor (DS102) | DS102 versus placebo | Efficacy and safety of orally administered DS102 in patients with acute AH/ NCT03452540 |
| Inflammation, IL-1 | IL-1 monoclonal antibody (canakinumab) | Canakinumab versus placebo | IL-1 signal inhibition in AH/ NCT03775109 |
| Neutrophils, Hepatic regeneration | Anakinra (plus zinc) and G-CSF (also known as filgrastim) | Anakinra (plus zinc) versus prednisone or placebo; G-CSF versus prednisone or placebo | Trial of anakinra (plus zinc), G-CSF, or prednisone in patients with SAH/ NCT04072822 |
| G-CSF | G-CSF versus steroid or placebo | Efficacy and safety of G-CSF in patients with SAH with null or partial response to steroid/ NCT02442180 | |
| G-CSF | G-CSF + standard medical therapy versus standard medical therapy | GCSF in AH/ NCT03703674 | |
| Pegfilgrastim (pegylated form of filgrastim) | Pegfilgrastim + standard of care versus standard of care | Pegfilgrastim in patients with AH/ NCT02776059 | |
| Hepatic regeneration | IL-22 (F-652) | F-652 dose escalation | Use of F-652 in patients with AH/ NCT02655510 |
| Gut microbiota | Probiotics | Probiotic Lactobacillus rhamnosus GG versus placebo | Novel therapies in moderately severe acute AH/ NCT01922895 |
| Immunomodulation, Gut permeability | Bovine colostrum (IMM-124E) | IMM-124E versus placebo | Comparison of bovine colostrum versus placebo in treatment of SAH: A randomized double-blind controlled trial/ NCT02473341 |
| Oxidative stress, Infection | Antioxidant (N-acetylcysteine, NAC) | NAC + prednisolone versus prednisolone | N-acetylcysteine to reduce infection and mortality for AH/ NCT03069300 |